antigenic regions located throughout the length of the protein molecule. Synthetic peptides 13 to 15 amino acid residues in length were synthesized for 10 such regions. Mice were immunized with each of the 10 synthetic peptides conjugated to keyhole limpet hemocyanin. An enzyme-linked immunosorbent assay (ELISA) of the antisera was performed by using each of the synthetic peptides as the ELISA antigen to verify that immunoglobulin G (IgG) antibodies capable of reacting with the peptide used as immunogen were elicited by each peptide. Each of the antipeptide antisera was screened for the presence of IgG antibodies that could bind to the surface of intact cells of strains representing the seven heterologous Fisher-Devlin immunotypes of P. aeruginosa by use of an ELISA with whole cells of the various strains as the ELISA antigen. Three peptides elicited antibodies capable of reacting with whole cells of all seven immunotype strains. Peptide 10, corresponding to amino acid residues 305 to 318, elicited whole-cell-reactive antibodies at high titers. Peptide 9, corresponding to amino acid residues 261 to 274, elicited whole-cell-reactive antibodies at more intermediate titers. Peptide 7,  corresponding to amino acid residues 219 to 232, elicited such antibodies only at low titers.
The carboxy-terminal portion of the mature protein appears to be the immunodominant portion. In particular, peptides 10 (NATAEGRAINRRVE) and 9 (TDAYNQKLSERRAN) appear to have potential for use as immunogens in a synthetic vaccine for immunoprophylaxis against infections caused by P. aeruginosa. Antisera from mice immunized with either peptide 9 or 10 mediated opsonophagocytic uptake by human polymorphonuclear leukocytes of wild-type cells of P. aeruginosa but exhibited no opsonic activity against a protein F-deficient mutant of P. aeruginosa.
Our laboratory group has previously demonstrated that outer membrane (OM) protein F (OprF in the proposed nomenclature of Hancock et al. [13] ) ofPseudomonas aeruginosa has efficacy as a vaccine upon active immunization to prevent subsequent infections by P. aeruginosa in animal models, including a murine acute-infection model (10) , a burned mouse model (16, 17) , and a rat model of chronic pulmonary infection (8, 9) . Protein F has many attributes that are desirable in a vaccine candidate. It is an important major OM protein (26) that is surface exposed in wild-type strains (14, 19) and whose loss renders mutants avirulent (17) . Protein F is present and immunologically cross-reactive in all strains of P. aeruginosa (4, 20) . Antibodies to protein F possess opsonophagocytic killing activity against P. aeruginosa (2, 8, 12) . Antibodies directed against protein F have been associated with protection in human infection (15) and in animal models (12, 18) . No cross-reactivity has been found between antibodies to protein F of P. aeruginosa and wild-type cells of other genera of gram-negative rods (4) . Recombinant protein F retains vaccine efficacy in the complete absence of P. aeruginosa lipopolysaccharide (17) . Immunization with protein F affords protection against all of the various heterologous Fisher-Devlin immunotype strains of P. aeruginosa (9, 16 Estimations of the hydrophilicity, probability of surface exposure, flexibility, and antigenic index of various sites throughout the length of the protein were calculated (Fig. 1) . Ten sites corresponding to regions with the highest predicted antigenic potentials based upon consideration of these four parameters were selected.
Synthetic peptides. The following 10 peptides (Fig. 2 ) were synthesized and provided as lyophilized powder by the Peptide Synthesis Unit of the Core Laboratories, Louisiana State University Medical Center Auxiliary Enterprises (New Orleans) (corresponding amino acid residues indicated): peptide 1, amino acid residues 7 to 19; peptide 2, residues 54 to 67; peptide 3, residues 98 to 111; peptide 4, residues 136 to 149; peptide 5, residues 177 to 190; peptide 6, residues 189 to 203; peptide 7, residues 219 to 232; peptide 8, residues 242 to 256; peptide 9, residues 261 to 274; and peptide 10, residues 305 to 318.
Immunization procedures. Each of the synthetic peptides was conjugated to keyhole limpet hemocyanin (KLH) (Calbiochem, San Diego, Calif.) in the following manner. To 25 mg of the peptide dissolved in 1 ml of sterile phosphatebuffered saline (PBS) (pH 8.3), 1 ml of a 20-mg/ml solution of KLH in sterile PBS was added. Three milliliters of a 0.2% glutaraldehyde solution in PBS was added dropwise to the mixture with stirring. Stirring was continued for 30 min at ambient temperature, after which 1.5 ml of a filter-sterilized 1 M solution of glycine in distilled water (pH 7.2) was added. Stirring was continued for an additional 30 min at ambient temperature. The peptide-KLH conjugate was then dialyzed against four 300-ml volumes of sterile PBS within 24 h by using dialysis tubing with a 3,500-molecular-weight cutoff. The conjugate was recovered, placed in sterile vials, and stored at -20°C until used. The sterility of the conjugate was checked by plating one drop from the conjugate onto nutrient agar prior to storage at -20°C and observing for any bacterial contamination after overnight incubation at 30°C.
For the first two immunizing doses (see below), the peptide-KLH conjugate was given with aluminum hydroxide adjuvant. Adsorption was accomplished by combining the conjugate with aluminum hydroxide (2.5 mg/ml), adjusting the pH to 5 with 1 N HCl, and allowing the adsorption to continue overnight at 4°C.
For each experiment, 20 5-week-old, specific-pathogenfree ICR mice (Harlan Sprague Dawley, Inc., Indianapolis, Ind.) were used per group. Thirteen groups were included consisting of mice immunized with cross-linked KLH alone, each of the 10 synthetic peptide-KLH conjugates, and protein F purified from the PAO1 strain of P. aeruginosa and from an E. coli strain into which the protein F gene had been cloned (25). Protein F was purified by gel extraction as described previously (10) . For the first two immunizations (days 0 and 14), each mouse received 0.2 ml of sterile saline containing either 150 ,ug of cross-linked KLH, 150 ,ug of peptide-KLH conjugate, or 10 ,ug of PAO1 protein F or E. coli-derived recombinant protein F, given with aluminum hydroxide adjuvant. The third and fourth immunizations (days 28 and 42) were given without adjuvant and consisted of 0.2 ml of sterile saline containing 15 ,g of cross-linked KLH alone, 15 ,ug of peptide-KLH conjugate, or 10 ,ug of the appropriate protein F preparation. All four immunizing doses were administered intramuscularly into alternate rear hips. Two separate immunization experiments were performed in this study. All animals used in this study were handled in accordance with the guidelines of the Louisiana State University Medical Center-Shreveport Animal Care and Use Committee.
Monitoring the antibody response. Two weeks after the fourth immunization (day 56), the mice were bled by cardiac puncture under sodium pentobarbital anesthesia, and the sera obtained were pooled for each group of mice. The antisera were used in two separate ELISAs to determine the titer of immunoglobulin G (IgG) antibodies to various antigens. The ELISA was performed as described previously (16) . For one assay, the synthetic peptides were used as the antigen. Flat-bottom, 96-well Immulon 1 microtiter plates (Dynatech Laboratories, Inc., Chantilly, Va.) were irradiated (3) face-up under a 15-W UV lamp for 20 min at ambient temperature. Each well of the UV-irradiated plates was immediately coated with 100 RI of a 25-,ug/ml peptide solution in borate-buffered saline (pH 8.3), and the plates were used immediately in an ELISA. Each of the 10 synthetic peptides was used as the antigen, and antiserum against each of the 10 peptides was assayed in comparison with the KLH control antiserum. For the second ELISA, whole cells were used as the antigen. Each well of the polyvinylchloride, flat-bottom, 96-well Falcon microtiter plates (Becton-Dickinson and Co., Oxnard, Calif.) was coated with 100 ,ul of a P. aeruginosa cell suspension prepared by the method of Abdillahi and Poolman (1). P. aeruginosa cells were scraped off a nutrient agar plate that had been incubated overnight at 30°C and resuspended in 50 ml of sterile PBS (pH 7.2). The A660 was adjusted with sterile PBS to 0.09, which corresponds to approximately 108 cells per ml. The cells were incubated in a water bath at 56°C for 30 min, and then each well of the microtiter plate was coated with 100 ,ul of the cell suspension. The plates were incubated overnight at 37°C, wrapped in aluminum foil, and stored at ambient temperature for up to 2 months prior to use. Whole cells of the PAO1 strain, the KG1077 protein F-deficient strain, and strains representing Fisher-Devlin immunotypes 1 through 6 were used in these assays as antigens. Antisera from the KLH control group, from the 10 peptide-immunized groups, and from the PAO1 protein F and E. coli-derived protein F groups were assayed against these antigens. Computer-generated plots of the hydrophilicity, probability of surface exposure, flexibility, and antigenic potential of sites throughout the length of the mature 326-amino-acid protein F molecule. At the top of the figure, the approximate location of each of the 10 peptides chosen for synthesis is indicated by 1 through 10. For the ELISAs using synthetic peptides as antigens, three separate assays were performed for each of the antisera, and the mean titer + standard deviation (SD) was calculated for each of the antisera. For the ELISAs using whole cells as antigens, six to seven separate assays were performed for each of the antisera and the mean titer + SD was calculated for each of the antisera.
Adsorption of antisera with cells harvested from broth. Cells were grown overnight in nutrient broth at 30°C with shaking to a cell concentration of approximately 3 x 109/ml. Cells from 10 ml of broth culture were pelleted by centrifugation at 3,500 x g for 10 min. A 0.5-ml volume of antisera was added to the pelleted cells, the cells were resuspended, and the mixture was incubated at 37°C for 15 min with gentle shaking. The antiserum-cell mixture was centrifuged in a microcentrifuge tube to remove the cells, and the serum was transferred to another cell pellet from 10 ml of broth culture, mixed, and incubated as described before. Each of the antisera was adsorbed six times with cell pellets. After the sixth and final adsorption and centrifugation, the serum was transferred to a Z-spin microcentrifuge tube with a 0.2-,um filter membrane (Gelman Sciences, Ann Arbor, Mich.) to remove residual bacterial cells. The broth culture-adsorbed antisera were compared with unadsorbed antisera in ELISAs using whole cells of the strain used for adsorption and whole cells of another heterologous Fisher-Devlin immunotype strain to determine the effect of adsorption on the titer in the antisera of IgG antibodies that bind to whole cells nate rear hips at 2-week intervals. Two weeks after the fourth immunization, sera were collected by cardiac bleeding and pooled for each vaccine group. The antisera were analyzed by an ELISA using the synthetic peptides as the antigens to determine whether the immunization protocol ISA plates. The antisera to peptides 9 and 10 were was successful in eliciting IgG antibodies directed against in ELISAs with the homologous peptide as antigen each of the 10 peptides. As shown in Table 1 , each peptide tine the effect of adsorption with broth culture cells elicited a significant titer of IgG antibodies reactive with the J titer of antibodies directed against the peptide. As homologous peptide. Eight of the 10 peptides had mean titers e control to demonstrate that the antibodies were of 2,560 to 10,240 against the homologous peptide. Although rbed nonspecifically, a K-12 strain of E. coli was peptides 1 and 5 had mean titers of 427 and 853, respectively, adsorb the immune antisera directed against the this level of antibodies was adequate for the purpose of this )tein F, peptide 9, or peptide 10, and the resultant study. Two of the peptides (peptides 6 and 7) elicited e determined in ELISAs.
antibodies that did not cross-react significantly with any of or opsonic activity of antisera. The ability of antisera the nine heterologous peptides ( antigenic sites on intact whole cells. The mean titers ± SD evaporation at 37°C overnight during the coating of the wells from six to seven determinations for each of the antisera of the microtiter plate. These manipulations could have after reaction with whole cells of the various P. aeruginosa exposed antigenic sites that were not exposed on the surface strains are given in Table 2 . The antisera from mice immuof whole cells which had not undergone such manipulations. nized with the KLH carrier cross-linked in the absence of To determine whether the antibodies elicited by the peptides the peptides did not react to any appreciable degree with the could react with whole cells that had not been manipulated in whole cells of the various strains. Three of the peptides this manner, we adsorbed the antisera directed against (peptides 7, 9, and 10) elicited antibodies capable of reacting peptides 9 and 10 with cells from a broth culture manipulated with whole cells of all seven Fisher-Devlin immunotype only by centrifugation during harvesting. Adsorption of the strains. Peptide 10 elicited antibodies at very high mean antisera resulted in a removal of antibodies from the antititers (6,190 to 8,960), whereas peptide 9 elicited antibodies sera, with a resultant decline in titers of antibodies upon at an intermediate range of mean titers (590 to 4,067).
subsequent ELISA using whole cells of either the strain used Neither of these two peptides elicited antibodies capable of for the adsorption or of a strain of a heterologous immunoreacting to a significant degree with whole cells of the protein type (Table 3 ). The adsorption with broth culture cells of the F-deficient KG1077 strain, which suggests that the antibodantisera to peptides 9 and 10 also resulted in a decline in ies are indeed recognizing protein F on the cell surface of antibody titer when measured by an ELISA using the reactive strains. Peptide 10 was capable of eliciting antibodspecific peptide as antigen. Adsorption of antisera directed ies reactive at higher mean titers with the various strains of against peptide 9 with cells of the Fisher-Devlin immunotype P. aeruginosa than were the antibodies elicited by recombi-3 strain reduced the ELISA titer for peptide 9 to 5,120 from nant protein F purified from the E. coli strain (Table 2) . a titer of 10,240 for unadsorbed antisera, whereas adsorption Peptide 7 elicited antibodies that reacted at low mean titers of the antipeptide 9 antisera with cells of the Fisher-Devlin (32 to 126) with all of the strains; however, these antibodies immunotype 6 strain reduced the titer for peptide 9 to 2,560. also reacted to the protein F-deficient strain with a mean titer Adsorption of antisera directed against peptide 10 gave of 71. similar results. From an initial titer of 25,600 for unadsorbed The preparation of the ELISA plates coated with whole antisera in an ELISA using peptide 10 as antigen, adsorption cells of P. aeruginosa involved heating the cell suspension at with cells of either the Fisher-Devlin immunotype 3 or 56°C for 30 min and then allowing the cells to dry by immunotype 6 strain resulted in a decline in the ELISA titer (Tables 1 and 2 ). The simplest explanation of these data is that these peptides are surface exposed within the OM of whole cells. These findings would indicate that the carboxy-terminal end of mature protein F is immunodominant and that various regions in the carboxy-terminal portion of protein F are surface exposed. Previous analysis of the gene for protein F had revealed greater homology to the OmpA protein of E. coli than to the E. coli porins (OmpF, OmpC, LamB, and PhoE) (5, 24) . This had raised the possibility that the carboxy-terminal end of protein F might be contained within the periplasmic space in a manner similar to that of OmpA (7). Our results indicate that this is As another means of indicating surface accessibility of the peptides and of measuring the functional activity of antisera directed against the synthetic peptides, we determined the ability of peptide-directed antisera to mediate the opsonophagocytic uptake of P. aeruginosa cells. In a preliminary screening experiment, antisera directed against peptides 1 to 8 appeared to lack any opsonic activity against wild-type Fisher-Devlin immunotype 2 cells. However, antisera directed to peptides 9 and 10 did mediate the opsonophagocytic uptake by human PMNs of the immunotype 2 cells (Table 4) . Exposure of the wild-type cells to antisera against peptide 9 PMNs after exposure to the immune antisera appeared to be mediated by antibodies specific for protein F since no significant difference was seen in the uptake of the protein F-deficient KG1077 cells by the PMNs after exposure of the KG1077 cells to either normal sera, KLH control sera, or antipeptide 9, antipeptide 10, or anti-E. coli protein F sera (Table 4 ). Demonstration of opsonic activity by antisera to peptides 9 and 10 supports the potential usefulness of these two synthetic peptides as a vaccine since protective antibodies might be expected to function as opsonins.
In summary, we have identified three peptides, each 14 amino acids in length, that appear to contain linear B-cell epitopes that are capable of eliciting antibodies that bind to the surface of whole cells of P. aeruginosa. Two of these peptides, peptide 9 (representing residues 261 to 274 of mature protein F) and peptide 10 (representing residues 305 to 318), elicit whole-cell-reactive antibodies at sufficiently high titers to suggest they may have potential usefulness as a synthetic vaccine for P. aeruginosa. Antisera to peptides 9 and 10 possess opsonic activity against wild-type cells of P. aeruginosa, indicating that antibodies directed against these two peptides have potentially protective capabilities. Proof of the efficacy of these peptides as a vaccine will require further experimentation in which their ability to afford protection against subsequent challenge with P. aeruginosa is assessed in animal models upon active immunization.
